Bharat Biotech launches typhoid drug
Aug 27 2013 , Hyderabad
Bharat Biotech is the first company to bring a conjugate version. Multinationals like Sanofi and GSK have a polysaccharide version.
The typhoid segment is expected to bring Rs 70 crore to the company.
“We have invested around Rs 65 crore. And typically, the investments would reap benefit only after 10 to 15 years. But we hope with this new drug we willbe able to reach out to more countries,” said Krishna Ella, chairman and managing director of Bharat Biotech.
It is said conjugate version, which can be given above the age of six months, provides immunity from the disease for longer duration.